This year’s IDWeek (Oct 19-22, 2025) showcased a spectrum of therapeutics to protect against and treat Respiratory syncytial virus (RSV) infection across vulnerable populations: infants, older adults, and the immunocompromised. Once dominated by seasonal hospital surges and limited preventive options, RSV management is entering a new era characterized by durable vaccination strategies, next-generation monoclonal antibodies,…